Table 1.

Effect of seminal vesicle involvement on failure

SV
Study	# pts	PSA Failure	Months Med f/u (mean)	modifiers		Failure rate		5 yr DFS	7 yr DFS	10 yr DFS
Swanson16	35	>0.3	121	EPE- mar-		60%		47%		33%
	9			EPE+mar-		75%		33%		17%
	19			EPE+mar+		95%		10%		0%
Han22	113	>0.2	76					48%	30%	17%
Roehl24	NS	≥ 0.3	(65)							26%
Trapasso27	93	>0.4	34					40%
Sofer 29	10	>0.3	43	Gl 2-6		40%
	30			Gl 7		47%
	26			Gl 8-10		58%
	18			Cap pen		67%
	41			EPE		49%
	34			Mar+		56%
Stephenson30	195	≥ 0.2 x2	38	Mar+					21%
	224			Mar-					48%
Karakiewicz31	352	0.1-0.4	25	Mar-				43%		20%
	300			Mar+				19%		12%
Hull 32	81	0.4	47					37%		37%
Salomon33	137	>0.2	(59)			52%		34%		10%
D'Amico 34						PSA*
						0-4	20-50
	70 NS	>0.1	42*	Gl 8-10	Mar-	66%	96%
					Mar +	89%	99%
				Gl 7	mar-	55%	91%
					Mar+	79%	99%
				Gl 5-6	mar-	51%	88%
					Mar+	76%	99%
				Gl 2-4	mar-	36%	74%
					Mar+	59%	93%
Quinn 35	79	>0.4	39 (41)			30%
Tefilli 36	59	>0.4	43	Mar+				14%
	34			Mar-				49%
	70			PSA<10				59%
	23			PSA>10				17%
	8			Gl <7				45%
	85			Gl>7				22%
Freedland 37	135	≥ 0.2 x2	32					36%
	80			Mar +				21%
	55			Mar -				56%

Definition of failure and disease free survival: based on biochemical (PSA) failure and includes biopsy proven local recurrence and radiologically detected distant metastasis

* 2 year endpoint for all groups. Mar+ is margin positive; Mar- is margin negative; EPE+ is extraprostatic extension present; EPE- is extraprostatic extension absent; foc is focal; Ext is extensive; Est is established; Gl is Gleason score